Guided Therapeutics, Inc.
GTHP
$0.0831
-$0.0059-6.63%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 38.00K | 38.00K | 82.00K | 98.00K | 66.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 38.00K | 38.00K | 82.00K | 98.00K | 66.00K |
| Cost of Revenue | 18.00K | 22.00K | 55.00K | 62.00K | 125.00K |
| Gross Profit | 20.00K | 16.00K | 27.00K | 36.00K | -59.00K |
| SG&A Expenses | 1.61M | 1.71M | 2.72M | 3.26M | 3.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.10M | 2.16M | 3.05M | 3.55M | 3.99M |
| Operating Income | -2.06M | -2.12M | -2.97M | -3.46M | -3.92M |
| Income Before Tax | -2.15M | -2.17M | -3.02M | -3.49M | -4.91M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.15 | -2.17 | -3.02 | -3.49 | -4.91 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.15M | -2.17M | -3.02M | -3.49M | -4.91M |
| EBIT | -2.06M | -2.12M | -2.97M | -3.46M | -3.92M |
| EBITDA | -2.05M | -2.11M | -2.96M | -3.45M | -3.91M |
| EPS Basic | -0.04 | -0.04 | -0.06 | -0.07 | -0.10 |
| Normalized Basic EPS | -0.03 | -0.03 | -0.04 | -0.05 | -0.05 |
| EPS Diluted | -0.04 | -0.05 | -0.06 | -0.07 | -0.10 |
| Normalized Diluted EPS | -0.03 | -0.03 | -0.04 | -0.05 | -0.05 |
| Average Basic Shares Outstanding | 220.54M | 214.97M | 209.95M | 204.50M | 199.76M |
| Average Diluted Shares Outstanding | 220.54M | 214.97M | 209.95M | 204.50M | 199.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
